pharma · Schizophrenia · Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis · MPLT
MapLight Therapeutics
MapLight Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- atlanta, USA
- Founded
- 2017
- Employees
- 7
- Programs
- 5
- Drugs
- 5
- Patents
- 0
MapLight Therapeutics projects
5 ClinicalTrials.gov programs sponsored by MapLight Therapeutics.
MapLight Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ML-004 (IR)/(ER) tablet
MapLight Therapeutics
Autism Spectrum Disorder
2 trials -
ML-007C-MA
MapLight Therapeutics
Psychosis Associated With Alzheimer's Disease
2 trials -
ML-007C-MA
MapLight Therapeutics
Schizophrenia
1 trial -
Placebo
MapLight Therapeutics
Schizophrenia
1 trial -
Placebo for ML-007C-MA bilayer tablet
MapLight Therapeutics
Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
1 trial
Frequently asked questions
How many clinical projects does MapLight Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.